Sponsors (2)
Introduced September 10, 2025 by Buddy Carter · Last progress September 10, 2025
The bill increases transparency and enforcement to better target 340B savings to low‑income patients and strengthen program integrity, but it also creates substantial new reporting, compliance, and penalty risks that may strain safety‑net and rural providers and could reduce access or raise costs for some patients.
Hospitals, covered entities, manufacturers, states, and patients: the bill creates standardized registration, annual reporting, claim-level indicators, and stronger audit/enforcement tools so federal and state actors can detect and reduce improper 340B use and improve program integrity.
Low-income, uninsured, and Medicaid/Medicare patients: the bill increases protections that help preserve or expand access to discounted drugs (expanded eligible hospitals, retention of 340B savings by covered entities, restrictions on PBM clawbacks, and charity-care requirements), potentially lowering out‑of‑pocket costs and supporting safety‑net services.
Hospitals and covered entities: a clearer federal standard across states reduces state-by-state regulatory variation and litigation, simplifying compliance and lowering some administrative complexity.
Hospitals, clinics, contract pharmacies, and small providers: the bill imposes extensive new administrative, IT, registration, reporting, and recordkeeping requirements that will increase operational costs and staff time.
Rural, safety‑net, and smaller providers: heightened documentation, certification, registration, and audit exposure raise the risk that some child sites, CAHs, rural emergency hospitals, subgrantees, or small contract pharmacies cannot comply and will lose 340B access, reducing local access to affordable drugs.
Hospitals, pharmacies, and patients served by them: the bill creates substantial financial exposure through repayments to manufacturers, high civil monetary penalties (per-claim or per-day), and interest that could produce large unexpected liabilities and threaten providers' finances.
Based on analysis of 38 sections of legislative text.
Comprehensively reforms 340B oversight: tightens eligibility, requires claims-level reporting and a clearinghouse, limits contract pharmacy/TPA payments, adds audits/penalties, and mandates sliding fee caps for low‑income patients.
Strengthens oversight, transparency, and compliance rules for the federal 340B drug discount program by requiring detailed annual reporting, claims-level data submissions, a third-party claims clearinghouse, and new audits and penalties for noncompliance. It tightens eligibility rules for hospitals and nonhospital covered entities, limits and regulates use of contract pharmacies and third‑party administrators, requires sliding fee scales and caps on out‑of‑pocket costs for low‑income patients, and bans discriminatory practices by insurers and PBMs. The measure creates multiple new HHS rulemaking and implementation deadlines (including interim rules and guidance within 180 days and required regulations within 1 year), establishes civil monetary penalties and repayment obligations for improper 340B purchases, preempts most state or local 340B laws, and generally becomes effective one year after enactment unless a different date is specified.